Hims & Hers stock forecast: Buyer support underpins breakout attempt

Traders Union
All News
Stocks
Hims & Hers jumps 4.71% today

Highlights

Hims & Hers Health faces a securities class action and a Federal Trade Commission complaint over allegations of unauthorized health data sharing and charging for prescriptions before medical consultations.
Legal proceedings expose the company to substantial litigation risk, higher compliance costs, and operational uncertainty that may increase near-term volatility for shareholders.
Shares of Hims & Hers advanced 4.71% today, with technical signals mixed and the stock expected to consolidate in the $27.66 to $29.96 range over the next 2 to 3 days.

Legal risk rises as class action links to FTC complaint

Hims & Hers Health is facing heightened legal and regulatory scrutiny following confirmation of a securities class action lawsuit, which alleges the company shared consumer health information with third-party advertising platforms and charged for prescriptions before completion of required medical consultations, according to Globenewswire. This lawsuit is directly connected to a federal complaint filed by the Federal Trade Commission on July 29, 2026, as reported by PR Newswire, accusing the firm of violating the Restore Online Shoppers' Confidence Act. These actions expose Hims & Hers Health to significant legal risk, higher compliance costs, and operational uncertainty, which could contribute to elevated volatility in investor sentiment in the near term.

Mixed momentum and overbought signals as volatility surges

On the hourly chart, HIMS trades above its MA-20 at $28 and MA-50 at $27.9, while on the daily timeframe it sits above the MA-200 at $28.19. The Ichimoku Kijun provides immediate support at $28.08. Momentum signals present a mixed picture: MACD and ADX indicate persistent buying pressure, while Stoch RSI flashes a strong sell warning, and Bull/Bear Power shows overbought conditions with buyers dominating intraday action. RSI stands at 59.69 and CCI signals a buy, further supported by a bullish Awesome Oscillator. Intraday volatility is high, with HIMS closing near the top of its daily range and a slight negative gap at the open, suggesting that gains may be stretched in the short term.

Rangebound trade likely as momentum supports modest upside

Over the next 23 sessions, HIMS is likely to consolidate within the $27.6629.96 range, reflecting the band of typical volatility for recent conditions. There is a moderate 57% chance of upward continuation, based on the interplay of mixed but generally supportive trend indicators and strong momentum signals. If HIMS breaks above the upper resistance, a further acceleration of gains could unfold, whereas a dip below immediate support at $28.08 may trigger additional downside and profit-taking.

Viktoras Karapetjanc, analyst at Traders Union, highlights that Hims & Hers Health demonstrates strong price action and resilient momentum despite new legal and regulatory challenges. He sees the confirmed class action and FTC complaint as significant risks, but notes that investor sentiment remains constructive in the short term. Support from technical indicators suggests buyers still dominate, with consolidation likely above key moving averages. The expert believes bullish momentum could persist if the company manages rising compliance headwinds. "Legal scrutiny elevates uncertainty, but current trends favor upside for agile investors," says Karapetjanc.

Earlier, analysts noted that Hims & Hers faced persistent technical headwinds along with regulatory risks, resulting in a cautious outlook for the stock. The emergence of a securities class action lawsuit and linked federal complaint now heightens operational and compliance uncertainty, making $28.08 an essential support level for traders to monitor as short-term volatility remains elevated.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.